GRAMD1B

Across TCGA pan-cancer cohorts, GRAMD1B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GRAMD1B data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GRAMD1B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GRAMD1B expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, LUSC, and LUAD are the cancer types where GRAMD1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.945	0.605	.002	34	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	21	view →
LUAD	OS	Median	II,III,IV	0.266	0.749	.027	6	view →
STAD	DFS	Median	All	1.000	0.391	.049	3	view →
BLCA	OS	Median	III,IV	0.188	0.654	.015	3	view →
SKCM	OS	Median	All	1.000	0.867	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GRAMD1B–UCEC (DFS)

Open the UCEC breakdown →